Management of hypertension in diabetic patients: Outstanding issues

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 6, 2011, Pages 721-728

  Camafort Babkowski, Miguel ^a   Barrios, Vivencio ^b   Coca, Antonio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

blood pressure control; cardiovascular disease; hypertension; T2DM mellitus

Indexed keywords

AMLODIPINE; ATENOLOL; CAPTOPRIL; ENALAPRIL; ENALAPRIL MALEATE PLUS HYDROCHLOROTHIAZIDE; ENALAPRIL MALEATE PLUS NITRENDIPINE; EPLERENONE; FELODIPINE; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; IRBESARTAN; LOSARTAN; METFORMIN; NISOLDIPINE; PLACEBO; RAMIPRIL; SPIRONOLACTONE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIURETIC THERAPY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RECURRENT DISEASE; REVIEW; RISK REDUCTION; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 79959910112     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.77     Document Type: Review

References (32)

1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008) (Pubitemid 351214285)
2. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342, 905-912 (2000) (Pubitemid 30177050)
3. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 821-826 (2005) (Pubitemid 41224805)
4. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension a randomized controlled trial. JAMA 292, 2227-2236 (2004) (Pubitemid 39473160)
5. Williams B, Poulter NR, Brown MJ et al.; British Hypertension Society. Guidelines for management of hypertension report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J. Hum. Hypertens. 18, 139-185 (2004) (Pubitemid 38425770)
6. Whaley-Connell A, Sowers JR. Hypertension Management in Type 2 diabetes mellitus: recommendations of the Joint National Committee VII. Endocrinol. Metab. Clin. N. Am. 34, 63-75 (2005) (Pubitemid 40332503)
7. MCFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 86, 713-718 (2001) (Pubitemid 32207485)
8. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am. J. Hypertens. 16, 41S-45S (2003) (Pubitemid 37449438)
9. Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of arterial Hypertension. J. Hypertens. 25, 1751-1762 (2007) (Pubitemid 47356612)
10. Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121-2158 (2009)
11. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 34(Suppl. 1), S11-S61 (2010)
12. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 27, 923-934 (2009)
13. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolichypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276, 1886-1892 (1996) (Pubitemid 26419185)
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 317, 703-713 (1998)
15. Bakris GL, Sarafidis PA. Antihypertensive treatment with b-blockers and the spectrum of glycaemic control. QJM 99, 431-436 (2006) (Pubitemid 44304843)
16. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med. 359, 1565-1576 (2008)
17. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61, 1086-1097 (2002) (Pubitemid 34175478)
18. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and Type 2 diabetes. Circulation 107, 753-756 (2003) (Pubitemid 36222605)
19. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff S, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N. Engl. J. Med. 338, 645-652 (1998) (Pubitemid 28108434)
20. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340, 677-684 (1999) (Pubitemid 29110751)
21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000)
22. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351, 1755-1762 (1998) (Pubitemid 28269185)
23. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001)
24. Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001)
25. Berthet K, Neal BC, Chalmers JP et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Blood Press. 13, 7-13 (2004) (Pubitemid 38455840)
26. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007)
27. The ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010)
28. Kurukulasuriya LR, Sowers JR. Therapies for Type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc. Diabetol. 9, 45 (2010)
29. Bangalore S, Parkar S, Grossman E, Messerli FH. A metaanalysis of 94,492 patients with hypertension treated with b blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100, 1254-1262 (2007) (Pubitemid 47498283)
30. Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am. J. Hypertens. 16, 381-386 (2003)
31. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am. Heart J. 160, 915-921 (2010)
32. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med. 359, 1565-1576 (2008).